title: Factors predicting mortality in invasive pneumococcal disease in adults in Alberta.
abstract: To define the factors associated with 30-day mortality among adult patients with invasive pneumococcal disease (IPD), we conducted a retrospective review of all cases of IPD in Alberta from 2000 to 2004. We hypothesized that multiple factors would be predictive of such mortality. We also examined the factors predictive of early (within 5 days of admission) mortality. We identified 1154 patients who met our inclusion criteria, 163 (14.1%) of whom died within 30 days. Over half (62.6%) of the deaths occurred within 5 days of admission. Ten factors were independently associated with increased 30-day mortality: 3 comorbidity factors-cancer within 5 years of diagnosis of IPD, diabetes, and cirrhosis; 4 complications-requirement for supplemental oxygen, mechanical ventilation, alteration of mental status, and cardiac arrest; 2 microorganism-related factors-infection with high- or infection with intermediate-mortality serotypes; and 1 treatment-related factor-treatment with a single antibiotic. Age 18-40 years and treatment with 2 antibiotics concurrently were associated with lower 30-day mortality. Comorbid illnesses were not contributory to early mortality (within 5 days of admission); instead, complications (alteration of mental status, requirement for supplemental oxygen, mechanical ventilation, and cardiac arrest) as well as infection with high-mortality serotypes and treatment with a single antibiotic were important. Age 18-40 years, infection with serotypes in the polysaccharide vaccine, and treatment with 2 or more than 2 antibiotics were associated with decreased early mortality. Early mortality accounted for 62.6% of the deaths. In conclusion, we found that mortality in IPD is multifactorial, the factors differ for 5- and 30-day mortality, and mortality is associated with host (age and complications), microorganism (pneumococcal serotypes), and therapeutic factors. Our data indicate that treatment with 2 or more antibiotics effective against Streptococcus pneumoniae should be used to treat IPD.
authors.affiliation: From Department of Medicine (TJM), Dalhouise University, Halifax, Nova Scotia; Department of Laboratory Medicine and Pathology (GJT, SG), University of Alberta, Edmonton, Alberta; National Centre for Streptococcus (GJT), Edmonton, Alberta; and Department of Pediatrics (OGV), University of Calgary, Calgary, Alberta, Canada.
authors.forename: Thomas James
authors.initials: TJ
authors.lastname: Marrie
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Tyrrell
authors.forename: Sipi
authors.initials: S
authors.lastname: Garg
authors.forename: Otto G
authors.initials: OG
authors.lastname: Vanderkooi
mesh_terms: D000293:Adolescent; D000328:Adult; D000416:Alberta / Q000453:epidemiology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003072:Cognition Disorders / Q000453:epidemiology*; D015897:Comorbidity; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008168:Lung / Q000382:microbiology; D018942:Macrolides / Q000627:therapeutic use; D008297:Male; D015999:Multivariate Analysis; D011008:Pneumococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality*; D051437:Renal Insufficiency / Q000453:epidemiology*; D012128:Respiratory Distress Syndrome / Q000453:epidemiology*; D012189:Retrospective Studies; D013296:Streptococcus pneumoniae / Q000302:isolation & purification; D016896:Treatment Outcome; D014640:Vancomycin / Q000627:therapeutic use; D055815:Young Adult; D047090:beta-Lactams / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D018942:Macrolides; D047090:beta-Lactams; D014640:Vancomycin